Development, preparation and safety testing of a Clostridium welchii type C toxoid. I: preliminary observations in man in Papua New Guinea.
The reactogenicity and immunogenicity of various strengths of plain and adsorbed Cl. welchii type C toxoid have been evaluated in laboratory tests and in man in Papua New Guinea. The greater antigenicity and acceptable clinical reactivity of a vaccine containing 50 total combining power units per 0.5 mm of adsorbed toxoid resulted in its selection for further field studies.
D000328:Adult; D000818:Animals; D000992:Antitoxins / Q000032:analysis; D002648:Child; D002986:Clinical Trials as Topic; D003015:Clostridium Infections / Q000517:prevention & control*; D003016:Clostridium perfringens / Q000276:immunology*; D004306:Dose-Response Relationship, Immunologic; D006168:Guinea Pigs; D006801:Humans; D051379:Mice; D009512:New Guinea; D011817:Rabbits; D013997:Time Factors; D014121:Toxoids / Q000276:immunology / Q000302:isolation & purification / Q000592:standards* / Q000627:therapeutic use; D014611:Vaccination
D000992:Antitoxins; D014121:Toxoids